EUCTR2009-012082-54-DE进行中（未招募）不适用
A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BIODEL inc.
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age: =19 to =65 years
- •2. Body Mass Index: =18 - =28 kg/m2
- •3. Diagnosed with Type 1 Diabetes Mellitus for at least 1 year
- •4. Insulin antibody less than or equal to 10 µU/mL at screening
- •5. Non-smoker, defined as no nicotine consumption for at least one year.
- •6. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Type 2 Diabetes Mellitus
- •2. C-peptide value of >1.0 ng/mL
- •3. HbA1c value of > 10.0%
- •4. History of hypersensitivity to any of the components in the study medication
- •5. History of severe or multiple allergies
- •6. Treatment with any other investigational drug in the last 3 months before study entry
- •7. Any systemic treatment with drugs known to interfere with glucose metabolism such as systemic corticoids, non-selective beta-blockers, and monoamine oxidase (MAO) inhibitors within 3 months prior to randomization.
- •8. Changes (type of drug or dose) in concomitant medication other than insulin in the last 3 weeks prior to randomization.
- •9. Use of non-prescription drugs, except routine vitamins, within 3 weeks prior to the first dose of the test drug. Occasional use of paracetamol/acetaminophen is permitted.
- •10. Progressive disease likely to prove fatal (e.g. malignancies)
- •11. Current drug or alcohol abuse, or a history of drug or alcohol abuse which in the opinion of the Investigator will impair subject safety or protocol compliance
- •12. Significant cardiovascular, respiratory, gastrointestinal, hepatic, renal, neurological, psychiatric and/or hematological disease as evaluated by the Investigator
- •13. Clinically significant abnormal hematology or biochemistry screening tests, as judged by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT >2 times the upper limit of normal) or impaired renal function (serum creatinine values above the upper limit of normal) will not be allowed to enter the trial.
- •14. Any serious systemic infectious disease during the four weeks prior to the first dose of study drug, as judged by the Investigator.
- •15. History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose a risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (hemoglobin below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.
- •16. Blood donation within the last 30 days
- •17. A woman who is lactating
- •18. Pregnant women or women intending to become pregnant during the study
- •19. A sexually active woman - not using adequate contraceptive methods (adequate contraceptive measures include: implants, injectables, combined oral contraceptives, hormonal IUD, sexual abstinence or vasectomized partner)
- •20. Positive serology for HIV, Hepatitis B or Hepatitis C
- •21. Abnormal ECG, safety lab or physical examination results that are deemed clinically significant by the Investigator
- •22. Lack of compliance or other reasons which, in the opinion of the Investigator, prevent the participation of the subject in the study.
研究者
相似试验
进行中（未招募）
不适用
A Single-Center, Double Blind, Randomized Crossover Study Evaluating Injection Site Toleration of VIAject® 7, VIAject® 25 and Insulin Lispro in Subjects with Type 1 or Type 2 Diabetes MellitusType 1 or Type 2 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-013264-39-DEBIODEL inc.
已完成
不适用
To study effect of food Supplement on blood parameters, after consuming alcoholic drink.CTRI/2019/11/022060PrARAS BIOSCIENCES PVT LTD30
进行中（未招募）
不适用
Efficacy compared between bilastine, desloratadine, rupatadine and placebo in reduction of histamine-induced skin reactivity in healthy volunteers.ALLERGIC RHINOCONJUNTIVITIS AND CHRONIC URTICARIAEUCTR2015-000790-13-ESFAES FARMA, S.A.
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.Hypercholesterolemia and Mixed DyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-002516-26-FRaboratoires Merck Sharp & Dohme-Chibret2,370
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia. - MK-0524B Lipid StudyHypercholesterolemia and Mixed DyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-002516-26-SEMerck Sharp & Dohme (Sweden) AB2,370